Taysha Gene Therapies Inc. (TSHA)
TSHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/0001193125-26-115202-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TSHA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001806310 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.8M |
| Net income | -$109.0M |
| Operating income | -$110.5M |
| Net margin | -1115.3% |
| Operating margin | -1130.6% |
| Revenue growth | +17.3% |
| Cash | $319.8M |
| Total assets | $343.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 135.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $422.8M cash; operating cash flow -$35.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 326,045,530 (2026-11-12); 273,919,373 a year earlier; 186,960,193 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Chicago, Illinois, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$39.1M | -$32.9M | $422.8M | $47.3M | $5.5M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$46.6M | -$40.4M | $455.4M | $49.3M | $5.5M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$42.4M | -$40.9M | $276.6M | $49.0M | $7.5M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $5.5M | -$27.9M | -$26.7M | $319.8M | $50.1M | $9.8M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $0 | -$32.7M | -$24.2M | $297.3M | $50.9M | $6.3M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $2.0M | -$26.9M | -$20.2M | $312.8M | $41.1M | $8.1M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $2.3M | -$21.5M | -$22.0M | $116.6M | $42.5M | $7.2M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $2.0M | -$18.8M | -$18.3M | $139.0M | $43.9M | $8.3M | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-25 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 404 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.3% |
| 1 month | +14.5% |
| 3 months | -31.6% |
| Year to date | -25.5% |
| 1 year | +2.2% |
| From 52-week high | -41.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVAX | Novavax Inc. | $8.06 | -5.45% | $1.3B |
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| VOR | Vor Biopharma Inc. | $18.97 | -2.32% | $1.2B |
| INBX | Inhibrx Biosciences Inc. | $77.66 | -6.77% | $1.1B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier